Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medicinal composition for treating Parkinson disease

A technology of Parkinson's disease and composition, which is applied in the direction of drug combination, medical formula, nervous system diseases, etc., can solve the problems of ineffective prevention and treatment of rapid development of PD, large toxic and side effects, and inaccurate curative effect, so as to improve blood flow in the brain , quality controllable, and the effect of improving the quality of life

Inactive Publication Date: 2011-04-06
KPC PHARM INC
View PDF0 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0011] The therapeutic goal of these drugs is to restore the balance of DA energy and Ach energy nervous system functions, but most of them have shortcomings such as inaccurate curative effect or large toxic and side effects, and they are attempts based on a certain link in the corresponding pathogenesis. The rapid development of PD cannot be effectively prevented

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicinal composition for treating Parkinson disease
  • Medicinal composition for treating Parkinson disease
  • Medicinal composition for treating Parkinson disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0036] Embodiment 1: the preparation of composition

[0037] Take 50 g of total saponins of Panax notoginseng, add appropriate amount of water to heat to completely dissolve, the obtained aqueous solution is loaded onto a macroporous adsorption resin column D101 type and eluted with 30% ethanol, the eluate is collected, and concentrated under reduced pressure to complete dryness to obtain Panax notoginseng Triol group saponin 1#.

Embodiment 2

[0039] Take 50 g of total saponins of Panax notoginseng, add appropriate amount of water and heat to completely dissolve, and the obtained aqueous solution is loaded onto a macroporous adsorption resin column D101 and eluted with 40% ethanol, the eluate is collected, concentrated under reduced pressure to complete dryness, and Panax notoginseng is obtained Triol group saponin 2#.

Embodiment 3

[0041]Take 50g of Panax notoginseng total saponins, add appropriate amount of water and heat to completely dissolve, the obtained aqueous solution is loaded onto a macroporous adsorption resin column and eluted with 50% ethanol, the eluate is collected, concentrated under reduced pressure to complete dryness, and notoginseng triol is obtained Group saponin 3#.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the field of medicines, and discloses a medicinal composition for treating the Parkinson disease. The medicinal composition comprises the active component of panaxtrial saponins. Preferably, the panaxtrial saponins comprises 60-80wt% of ginsenoside Rg1, 5-15wt% of ginsenoside Re, 10-25wt% of notoginsenoside R1 in content. The panaxtrial saponins has effects on inhibiting SH-SY5Y cell viability loss caused by 6-hydroxydopamine in a dosage dependency mode and inhibiting PC12 cell apoptosis induced by MPP+, and has an obvious effect on inhibiting SH-SY5Y cell viability loss caused by 6-OHDA. Animal experiments show that the dopamine content is reduced in the corpus striatum of a Parkinson mouse model by the inhibition effect of the panaxtrial saponins in a dosage dependency mode. The results show that the panaxtrial saponins have a new application in preparing the medicine for treating the Parkinson disease and have a favorable clinical application prospect.

Description

technical field [0001] The invention relates to the field of medicine, in particular to the use of saponins of the nonoginsanol group in the treatment of Parkinson's disease. Background technique: [0002] Parkinson's disease (PD) is a neurodegenerative disease characterized by the loss of dopaminergic neurons (NDN) in the substantia nigra. Its incidence rate can increase with age, the incidence rate of over 50 years old is 500 people / 100,000, and over 60 years old is 1000 people / 100,000 per year, becoming a common disease second only to cerebrovascular disease. [0003] Although the pathogenesis of PD has been gradually recognized by people, it is related to genetics, environmental factors, infection, aging, oxidative stress, excessive free radical formation and lack of nerve growth factors, etc., and is the result of synergistic effects of various mechanisms. The cause of specific degeneration of dopaminergic neurons in the substantia nigra has not yet been clearly elucid...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/704A61P25/16
Inventor 龚云麒杨兆祥
Owner KPC PHARM INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com